Grant: Project Grant - Priority Announcement: Infection and Immunity
University of Toronto
$100,000.00
Monocyte derived cells and TNF family ligands in STING agonist therapy of cancer
FY 2022-23
Summary
The stimulator of interferon genes (STING) is an intracellular sensor that can detect DNA in the cytosol of cells. Normal cells have their DNA in the nucleus and mitochondria, but if a cell is infected or damaged, such as occurs in cancer, DNA can be released into the cell cytosol- a signal that something is wrong. This in turn causes the STING pathway to produce a molecule called type I interferon that stimulates the immune system. Recently, scientists have made synthetic molecules that stimulate STING, referred to as STING agonists. The idea is to use this for an immune system boost to improve responses to infections or cancer. STING agonists have shown great promise in mouse models of melanoma and other cancers. They are injected into the tumor and a few days later the tumor starts to disappear. This has been shown to require at least 2 kinds of immune cells, dendritic cells, and T cells, that work together to eliminate the tumor. We have recently shown that a third kind of cell, a monocyte, is also important in this therapy. We now are investigating how these monocytes contribute to the therapy. Although this therapy is working well in mice, so far it hasn't worked as well in the early clinical trials in humans. By understanding the details of what is working in the mouse model, we gain insight as to what to look for to see how the therapy is working in humans and to optimize the therapy to achieve the desired outcome.
Department
Program
Project Grant - Priority Announcement: Infection and Immunity
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
472908
Name
Watts Tania H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Immunology
Projecttitle
Monocyte derived cells and TNF family ligands in STING agonist therapy of cancer
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Infection and Immunity
Keyworddelim
Adu S100; Cancer; Cgas-Sting; Genetic Models; Inflammatory Monocytes; Melanoma; T Cells; Tissue Resident Memory T Cells (Trm); Tnfrsf9 (4-1bb); Tnfsf18 (Gitr)
Abstract
The stimulator of interferon genes (STING) is an intracellular sensor that can detect DNA in the cytosol of cells. Normal cells have their DNA in the nucleus and mitochondria, but if a cell is infected or damaged, such as occurs in cancer, DNA can be released into the cell cytosol- a signal that something is wrong. This in turn causes the STING pathway to produce a molecule called type I interferon that stimulates the immune system. Recently, scientists have made synthetic molecules that stimulate STING, referred to as STING agonists. The idea is to use this for an immune system boost to improve responses to infections or cancer. STING agonists have shown great promise in mouse models of melanoma and other cancers. They are injected into the tumor and a few days later the tumor starts to disappear. This has been shown to require at least 2 kinds of immune cells, dendritic cells, and T cells, that work together to eliminate the tumor. We have recently shown that a third kind of cell, a monocyte, is also important in this therapy. We now are investigating how these monocytes contribute to the therapy. Although this therapy is working well in mice, so far it hasn't worked as well in the early clinical trials in humans. By understanding the details of what is working in the mouse model, we gain insight as to what to look for to see how the therapy is working in humans and to optimize the therapy to achieve the desired outcome.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Watts, Tania H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~